- Home
- VSTM vs XFOR Comparison
VSTM vs XFOR Comparison
Compare VSTM & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | XFOR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | 143 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.7M | 407.5M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | VSTM | XFOR |
|---|---|---|
| Price | $5.92 | $4.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $16.50 | $9.00 |
| AVG Volume (30 Days) | ★ 1.9M | 376.8K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | N/A |
| Revenue Next Year | $72.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $4.01 | $1.35 |
| 52 Week High | $11.25 | $4.83 |
Technical Indicators
Market Signals| Indicator | VSTM | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 53.21 |
| Support Level | $5.48 | $3.57 |
| Resistance Level | $6.79 | $4.57 |
| Average True Range (ATR) | 0.38 | 0.23 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 45.34 | 37.68 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.